GlassScriptPhysician profile
Jane L Lynch
NPI 1750476164
$44,043.04
in general payments reported to CMS, 2019-2025
24 companies · $903 in 2025
The $903 reported for 2025 was more than what a typical Pediatric Endocrinology provider received nationally (typical 2025 total: $294).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $33K · 2020: $2,678 · 2021: $6,825 · 2022: $33.81 · 2023: $404 · 2024: $397 · 2025: $903.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,704.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,703.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk As | $37,674.56 | 2019-2021 | |
| Novo Nordisk INC | $4,906.11 | 2019-2025 | Sogroya, Wegovy, Norditropin |
| Beta Bionics, INC. | $224.37 | 2023-2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Contact Detach, Ilet Insulin Infusion Kit Inset |
| Sanofi-Aventis U.S. LLC | $147.20 | 2023-2025 | |
| Tolmar, INC. | $128.98 | 2023-2025 | Fensolvi |
| Kyowa Kirin, INC. | $122.42 | 2024-2025 | Crysvita |
| Abbott Laboratories | $120.37 | 2023-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Ascendis Pharma Endocrinology INC | $113.78 | 2023-2025 | Skytrofa |
| Eton Pharmaceuticals, INC. | $104.35 | 2025 | Alkindi, Increlex, Khindivi |
| Dexcom, INC. | $88.91 | 2019 | |
| Azurity Pharmaceuticals, INC. | $63.67 | 2025 | Triptodur |
| Insulet Corporation | $58.80 | 2019-2025 | Omnipod |
| Soleno Therapeutics, INC. | $55.61 | 2025 | Vykat Xr |
| Pfizer INC. | $53.90 | 2019-2025 | |
| Lilly USA, LLC | $52.96 | 2019-2023 | Baqsimi |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Arbor Pharmaceuticals, INC. | $35.80 | 2019 | |
| Medtronic Minimed, INC. | $31.16 | 2019 | |
| Neurocrine Biosciences, INC. | $22.19 | 2025 | |
| Abbvie INC. | $20.29 | 2025 | |
| Xeris Pharmaceuticals, INC. | $17.61 | 2024 | Gvoke Hypopen |
4 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jane Lynch listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.